Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Corporate Update (October 2025)
17 slides from Syndax Pharmaceuticals's corporate update, Oct 24, 2025
Slide 1: FDA Approval of Revuforj (revumenib) in R/R NPM1 Mutated AML
FDA Approval of Revuforj® (revumenib) in R/R NPM1 Mutated AML October 24, 2025
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Agenda for today's call
Agenda for today’s call Opening Remarks & Key Highlights 1 Michael Metzger, Chief Executive Officer Revuforj (revumenib) Label & Supporting Data 2 Dr. Nick Botwood, Head of R&D and Chief Medical Officer Delivering Revuforj to Patients 3 Steve Closter, Chief Commercial Officer Q&A Session 4 Syndax Ma
Slide 4: Revuforj is now FDA-approved for a second indication
REVUFORJ IS NOW FDA-APPROVED FOR A SECOND INDICATION FIRST AND ONLY MENIN INHIBITOR APPROVED FOR: Multiple acute leukemia subtypes Adults and children ≥1 Now approved for treatment of relapsed or refractory (R/R) year of age acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and
Slide 5: Revuforj is well positioned for near- and long-term success, with a $5B+ U.S. market
Revuforj is well positioned for near- and long-term success, with a $5B+ U.S. market opportunity across the R/R and 1L setting BEST-IN-CLASS FIRST-MOVER PROFILE ADVANTAGE ➢ Compelling clinical data across: ➢ Well established with HCPs — nearly 1 year ✓ Multiple genetic subtypes including, of commerc
Slide 6: Revuforj (revumenib) Label & Supporting Data
Revuforj (revumenib) Label & Supporting Data Dr. Nick Botwood, Head of R&D and Chief Medical Officer
Slide 7: R/R NPM1m AML is an area of high unmet need
R/R NPM1m AML is an area of high unmet need NPM1 mutations (NPM1m) are the most common ~1 in 3 patients with AML genetic alteration in AML1 have an NPM1 mutation1 Outcomes are poor for NPM1m patients who >50% of NPM1m patients relapse or are refractory to Tx relapse after 1L therapy2-3 Revuforj offe
Slide 8: Overview of Revuforj (revumenib) U.S. Prescribing Information
Overview of Revuforj (revumenib) U.S. Prescribing Information Indication: • Revuforj is a menin inhibitor indicated for: • the treatment of R/R acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year
Slide 9: Key data from AUGMENT-101 pivotal trial of Revuforj in R/R NPM1m AML
Key data from AUGMENT-101 pivotal trial of Revuforj in R/R NPM1m AML Key efficacy data from AUGMENT-101 included in Revuforj USPI 2.8 months 23% CR/CRh median time to CR/CRh 11% of pts. underwent HSCT (primary endpoint) 4.5 months following Revuforj median duration of CR/CRh Additional data from AUG
Slide 10: Comprehensive Revuforj data generation strategy underway
Comprehensive Revuforj data generation strategy underway to further solidify revumenib’s leading position Original FDA Published pivotal R/R Published promising Ph 1 FDA approval of approval NPM1m AML data rev + ven/aza 1L data second indication Initiate 1L REVEAL trials of rev + I.C. in 4Q25 2024 1
Slide 11: Delivering Revuforj to Patients
Delivering Revuforj to Patients Steve Closter, Chief Commercial Officer
Slide 12: Approval unlocks $2B U.S. market opportunity for Revuforj in R/R acute leukemia
Approval unlocks $2B U.S. market opportunity for Revuforj in R/R acute leukemia alone $5B+ TAM With the largest addressable population and anticipated U.S. Market Opportunity ($ B) duration of therapy, Revuforj is poised to become the largest targeted AML therapy $2B+ TAM Addressable AML population
Slide 13: Revuforj is positioned to lead in R/R NPM1m with an industry-leading profile
Revuforj is positioned to lead in R/R NPM1m with an industry-leading profile and solid foundation for success Strong prescriber base Excellent payer support Demonstrated ease of World-class commercial & HCP familiarity & reimbursement access to Revuforj team, proven track record ✓ Same HCPs treat bo
Slide 14: Three strategic imperatives to deliver for patients and drive Revuforj growth
Syndax will continue to focus on three strategic imperatives to deliver for patients and drive continued Revuforj growth 1 2 3 Leave no Deliver premium Engage all key appropriate HCP/patient stakeholders patient behind experience High-risk patients require rapid Complex patient journey makes it Crit
Slide 15: Syndax is on the road to profitability with two medicines
Two first- & best-in-class drugs $5B+ TAM Syndax is on the road to profitability with two medicines with multi-billion- dollar potential Two exceptional $5B+ TAM product launches 15
Slide 16: Fueled by a passion for patients
FUELED BY A PASSION FOR PATIENTS Lilah, diagnosed with R/R AML 16
Slide 17: Slide 17
Syndax Pharmaceuticals — Corporate Update (October 2025) on 6ix